Radiopharmaceutical therapy (RPT) is increasingly being recognized for its potential as a targeted oncology treatment modality. With its ability to selectively target and destroy cancer cells using radioactive isotopes, RPT has emerged as a promising approach in cancer therapy, with projected US sales of $2 billion in 2025. This blog aims to educate researchers, biotech professionals, and the scientific community on the science, therapeutic potential, and preclinical considerations of RPT, highlighting why this field is gaining traction.
Why Radiopharmaceuticals Are Gaining Attention
Radiopharmaceutical therapy offers several compelling advantages that are driving its growing recognition and adoption within the oncology community.
Growing Clinical Success
One of the most significant factors contributing to the rising interest in RPT is the growing body of clinical success stories. For instance, Pluvicto (Lu-177-PSMA-617) was approved in 2022 by the FDA and has shown remarkable efficacy in treating metastatic castration-resistant prostate cancer (mCRPC).
Clinical trials have demonstrated that Pluvicto can achieve substantial tumor control, even in patients who have exhausted other treatment options. Lutathera, is another RPT approved by the FDA in 2018 for the treatment of neuroendocrine tumors. These successes have sparked industry-wide interest and has paved the way for further exploration of radiopharmaceuticals in other cancer types.
In addition, on March 28, 2025, the FDA expanded the indication for Pluvicto for adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy.
Targeted Radiation Delivery
Radiopharmaceuticals offer a unique mechanism of action by delivering targeted radiation directly to tumors. This approach allows for the precise targeting of cancer cells while sparing healthy tissues, thus minimizing the collateral damage often associated with conventional radiation therapy. By focusing the therapeutic effects on the tumor cells, RPT can reduce side effects and improve the overall quality of life for patients.
Bridging Precision Therapy and Systemic Treatment
Radiopharmaceutical therapy (RPT) combines the precision of targeted therapy with the systemic delivery of radiation, offering a more selective approach than traditional chemotherapy, which harms both healthy and cancerous cells. This dual capability allows for effective treatment of both primary tumors and metastatic sites, making RPT a versatile option in the oncology arsenal.
How Radiopharmaceuticals Work: Alpha vs. Beta Emitters
The therapeutic efficacy of radiopharmaceuticals depends on multiple factors, including the type of radioactive particles emitted. In radiopharmaceutical therapy (RPT), understanding the differences between alpha and beta emitters is crucial for selecting the appropriate isotope based on tumor characteristics and treatment goals.
Alpha Emitters
Alpha particles are characterized by their short-range and high-energy emissions. Due to their limited penetration depth (typically a few cell diameters), alpha emitters are particularly effective at delivering intense, localized radiation to cancer cells while sparing surrounding healthy tissues.
This makes them ideal for targeting metastases and small clusters of cancer cells. However, the short range also means that precise delivery to the tumor site is critical to avoid off-target effects.
Beta Emitters
Beta particles, on the other hand, have a longer range and lower energy compared to alpha particles. This allows beta emitters to penetrate deeper into tissues, making them suitable for treating larger tumors or those with more diffuse cellular architecture. The longer range also provides a broader therapeutic window, but it may come with an increased risk of affecting adjacent healthy tissues.
Factors Influencing Design
The choice between alpha and beta emitters depends on several factors, including the biodistribution and pharmacokinetics, toxicity profile, and penetration range. Other important considerations include the half-life of the radioactive isotope, chelators, and targeting vector specificity and affinity (e.g., ligand or antibody).
For example, Lutetium-177 (a beta emitter) has a favorable half-life and emits beta particles that are effective for treating various tumor types. In contrast, Actinium-225 (an alpha emitter) delivers high-energy radiation over a short range, making it suitable for specific applications where precision is paramount.
Delivery Vehicles and Molecular Targets
The design of radiopharmaceuticals also involves selecting appropriate delivery vehicles and molecular targets. Antibodies, peptides, and small molecules can be used as targeting agents to recognize and bind to specific cancer cell markers. Advances in genomics and proteomics have enabled the identification of novel targets, enhancing the precision and efficacy of RPT.
For instance, Prostate-Specific Membrane Antigen (PSMA) is a well-known target in prostate cancer, and radiopharmaceuticals targeting PSMA have shown promising results in preclinical and clinical studies. Pluvicto (Lu‑177‑PSMA‑617) exploit this target and have demonstrated strong efficacy in both preclinical models and clinical trials, leading to FDA approval.
Designing a Radiopharmaceutical: From Molecule to Model
Designing an effective radiopharmaceutical involves a series of meticulous steps, from target selection to preclinical testing. This section delves into the detailed process of developing a radiopharmaceutical, emphasizing the importance of each stage in ensuring translational success.
Target Selection
The first step in designing a radiopharmaceutical is the selection of an appropriate molecular target, typically a biomarker or receptor that is overexpressed on cancer cells. The specificity of the target is crucial for the selective binding of the radiopharmaceutical, and precision of radiation delivery. Advances in molecular biology have facilitated the identification of new and highly specific targets, enhancing the potential efficacy of RPT.
Radiolabeling and Chelation
Once a target has been identified, the next step is to radiolabel a targeting molecule with a radioactive isotope. Radiolabeling involves attaching the radioactive isotope to the targeting molecule, a process that must be done with high precision to ensure stability and functionality.
Chelation, the process of chemically binding a metal to an organic molecule, is a critical component of radiopharmaceutical design. Chelating agents (e.g., DOTA, DfO) securely bind the radioactive isotope to the targeting molecule. The choice of chelating agent affects the stability, biodistribution, and overall effectiveness of the radiopharmaceutical.
Preclinical Models
Preclinical evaluation is essential for assessing the safety, efficacy, and pharmacokinetics of the radiopharmaceutical before it can proceed to clinical trials.
Various preclinical models are employed based on the indication and stage of the disease:
- Cell lines: Classical cell lines are a great first pass for target validation, efficacy testing and initial biomarker identification. Relatively cheap, well characterized, and highly scalable they provide a good first indication of compound efficacy.
- Patient-Derived (Xenograft) Organoids (PD(X)O): PD(X)Os are highly translatable 3D in vitro models derived by expanding tumor stem cells from primary (xenograft) tissues. They are kept in a 3D matrix and optimized medium conditions mimicking the tumor microenvironment, driving preserved tumor heterogeneity and genetic and expression profiles. Their scalability, allowing eg combination therapy screening, combined with High Content Imaging analysis allows for compound efficacy screening, but also analysing compound binding, penetration, and MoA.
- Cell Line-Derived Xenografts (CDX): CDX models involve implanting human cancer cell lines into immunocompromised mice. These models are relatively inexpensive, highly consistent, and well characterized, supporting reproducible preclinical evaluation. They provide a controlled environment to study tumor growth and response to treatment in vivo, making them useful for initial screening and optimization of radiopharmaceuticals.
- Patient-Derived Xenografts (PDX): PDX models are established by implanting tumor tissues originally obtained from patients into mice, where they are subsequently maintained through serial passaging in vivo. These models preserve the heterogeneity and complexity of the original tumors, offering a more clinically relevant context for evaluating the efficacy of radiopharmaceuticals. PDX models are particularly valuable for investigating how tumors with different genetic backgrounds and molecular characteristics respond to treatment.
- Orthotopic Models: Orthotopic models involve implanting tumors (PDX or CDX) into the original tissue site in the animal model or systemically for hematological malignancies. These models more accurately mimic the tumor microenvironment and metastatic behavior, providing insights into the therapeutic potential and challenges of RPT in a setting that closely resembles human cancer.
Dosimetry, Biodistribution, and Imaging Readouts
Dosimetry, biodistribution, and imaging readouts are critical components of preclinical evaluation:
- Dosimetry: Dosimetry quantifies radiation absorbed by tumors and healthy tissues to optimize efficacy while minimizing toxicity.
- Biodistribution: Biodistribution studies track how the radiopharmaceutical disperses, accumulates, and clears from the body, informing targeting efficiency and safety.
- Imaging Readouts: Imaging readouts using PET or SPECT enable real-time visualization of drug distribution and tumor targeting, supporting dose optimization and treatment planning
Translational Success
The integration of preclinical models such as CDX, PDX, orthotopic, and humanized systems with imaging platforms enables quantitative evaluation of radiopharmaceuticals prior to the clinical translation. These studies provide critical data on safety, biodistribution, pharmacokinetics, and therapeutic efficacy, helping to de-risk the development process and guide clinical trial design. This translational approach ensures that radiopharmaceuticals entering clinical trials have a higher likelihood of success, ultimately benefiting patients.
Conclusion
Radiopharmaceutical therapy is gaining traction as a targeted oncology treatment modality, offering a unique way to selectively target and destroy cancer cells using radioactive isotopes. The clinical success of therapies like Pluvicto and Lutathera demonstrate the promise of RPT, particularly in advanced or resistant tumors. Furthermore, preclinical evaluation using appropriate models and imaging platforms plays a pivotal role in ensuring the translational success of these innovative therapies.
As research and technology continue to advance, the field of radiopharmaceuticals holds great potential to revolutionize cancer treatment. By harnessing the power of radiation and precision medicine, RPT offers new hope for more effective cancer therapies. Researchers, biotech professionals, and the scientific community are encouraged to explore and contribute to this rapidly growing field, driving the future of oncology forward.
Discover how Crown Bioscience and the Medicines Discovery Catapult (MDC) collaboration can support your radiopharmaceutical research with advanced models and biodistribution expertise.
Explore available models at Crown Bioscience
